

**ClinicalTrials.gov PRS DRAFT Receipt (Working Version)**

Last Update: 04/05/2024 04:09

**ClinicalTrials.gov ID: NCT06359301**

## Study Identification

Unique Protocol ID: H-34

Brief Title: H-34 DELTA Revision Cup

Official Title: An Open Label, Observational, Prospective, Longitudinal Cohort Study to Evaluate Safety, Clinical and Radiographic Outcomes of Total Hip Arthroplasty With DELTA Revision Cup

Secondary IDs:

## Study Status

Record Verification: April 2024

Overall Status: Recruiting

Study Start: September 14, 2021 [Actual]

Primary Completion: March 31, 2026 [Anticipated]

Study Completion: March 31, 2029 [Anticipated]

## Sponsor/Collaborators

Sponsor: Limacorporate S.p.a

Responsible Party: Sponsor

Collaborators:

## Oversight

U.S. FDA-regulated Drug: No

U.S. FDA-regulated Device: No

U.S. FDA IND/IDE: No

Human Subjects Review: Board Status: Approved

Approval Number: 104/B/2020 dated 09 Sept. 2020

Board Name: Bioethics Committee of the Medical Center of Postgraduate Education

Board Affiliation: Centrum Medyczne Kształcenia Podyplomowego

Phone: 22-56-01-066

Email: Komisja.bioetyczna@cmkp.edu.pl

Address:

Bioethics Committee of the Medical Center of Postgraduate Education  
ul. Marymoncka 99/103

Data Monitoring: No

FDA Regulated Intervention: No

## Study Description

**Brief Summary:** THis study is aimed to provide a clinical and radiographic evaluation of 49 suitable subjects who underwent a total hip arthroplasty with DELTA Revision acetabular cup.

**Detailed Description:** This is an observational study designed to reflect real life clinical practice as closely as possible. Thus, clinicians are free to choose the method to implant and total hip arthroplasty in accordance with the current local Delta Revision acetabular cup Indication for Use and current clinical practice.

## Conditions

Conditions: Hip, Osteoarthritis

Keywords: revision

## Study Design

Study Type: Observational

Observational Study Model: Case-Only

Time Perspective: Prospective

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment: 49 [Anticipated]

Number of Groups/Cohorts: 1

## Groups and Interventions

Intervention Details:

Device: DELTA Revision acetabular cup

Total hip arthroplasty

## Outcome Measures

Primary Outcome Measure:

1. Harris Hip Score (HHS)

Overall score from 0 to 100, with 100 being the best outcome

[Time Frame: From preoperative to 2 years after surgery]

Secondary Outcome Measure:

2. ROM measurement

Functional changes in ROM measurements from pre-operative (baseline), discharge, 2 months, 6 months, 1 year and 2 years

[Time Frame: From preoperative to 2 years after surgery]

3. Oxford Hip Score (OHS)

Overall score from 0 to 48, with 48 being the best outcome

[Time Frame: From preoperative to 2 years after surgery]

4. Survival rate

Survival rate expressed with Kaplan-Meier estimator at 2 years after surgery

[Time Frame: 2 years]

5. Radiographic implant evaluation and stability assessment of the DELTA Revision acetabular cup

The treated hip is analyzed postoperatively based on anteroposterior and lateral x-rays view of the knee to check for radiographic stability and radiographically detectable complications

[Time Frame: From preoperative to 2 years after surgery]

6. Incidence, type and severity of all the Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Device Effects (ADEs), and Serious Adverse Device Effects (SADEs) occurred at each follow-up

[Time Frame: From preoperative to 2 years after surgery]

## Eligibility

**Study Population:** The study population consists of 49 consecutive subjects who underwent a THA with the DELTA Revision acetabular cup at the Independent Public Clinical Hospital Prof. Adama Grucy CMKP. Subjects who do not meet all the inclusion criteria or meet any exclusion criteria are excluded from study participation and should be considered as a Screening Failure. Subjects who meet all the inclusion criteria and none of the exclusion criteria and agree to participate in the study signing the Informed Consent Form are enrolled.

**Sampling Method:** Probability Sample

**Minimum Age:** 18 Years

**Maximum Age:**

**Sex:** All

**Gender Based:** No

**Accepts Healthy Volunteers:** No

**Criteria: Inclusion Criteria:**

- male or female in whom a decision has already been made to perform a total hip arthroplasty with DELTA Revision acetabular cup as per indication for use. The decision to implant DELTA revision acetabular cup must be taken prior to, and independently from the decision to enroll the patient. This decision should be made in accordance with routine clinical practice at the study site concerned.
- Age  $\geq$  18 years old
- All patients must give written informed consent approved by the study site's Institutional Review Board (IRB)/Ethical Committee (EC)
- Patient is able to comply with the protocol

**Exclusion Criteria:**

- Adult patients with any DELTA Revision acetabular cup contraindication for use as reported in the current local instruction for use.
- For female patients, current pregnancy and/or lactation or planning a pregnancy

## Contacts/Locations

**Central Contact Person:** Federica Azzimonti

Telephone: +39 377 5450940  
Email: federica.azzimonti@limacorporate.com

Central Contact Backup:

Study Officials: Jerzy Bialecki  
Study Principal Investigator  
Samodzielny Publiczny Szpital Kliniczny im. Prof. Adama Grucy CMKP

Locations: **Poland**  
Samodzielny Publiczny Szpital Kliniczny im. Prof. Adama Grucy CMKP  
[Recruiting]  
Otwock, Poland, 05-400  
Contact: Jerzy Bialecki

## IPDSharing

Plan to Share IPD: No

## References

Citations:

Links:

Available IPD/Information:

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services